Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Tapan M. Kadia"'
Autor:
Nicholas J. Short, Sangeetha Venugopal, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Walid Macaron, Courtney D. Dinardo, Naval Daver, Marina Konopleva, Gautam Borthakur, Elizabeth J. Shpall, Uday Popat, Richard E. Champlin, Rohtesh Mehta, Gheath Al-Atrash, Betul Oran, Elias Jabbour, Guillermo Garcia-Manero, Ghayas C. Issa, Guillermo Montalban-Bravo, Musa Yilmaz, Abhishek Maiti, Hagop Kantarjian
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-10 (2022)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Background Treated secondary acute myeloid leukemia (ts-AML)—i.e., AML arising from a previously treated antecedent hematologic disorder—is associated with very poor outcomes. The optimal frontline treatment regimen for these patients is uncertai
Autor:
Prithviraj Bose, Michael Andreeff, Tapan M. Kadia, Guillermo Garcia-Manero, Hagop M. Kantarjian, Kunhwa Kim, Jorge E. Cortes, Elias Jabbour, Kelly A. Soltysiak, Xiao Qin Dong, Cheri Klingner-Winton, Xuelin Huang, Nitin Jain, Graciela M. Nogueras-Gonzalez, Sherry Pierce, Kimberly Sheppard, Courtney D. DiNardo, Kiran Naqvi, Guillermo Montalban-Bravo, Gautam Borthakur, Naval Daver, Yesid Alvarado, Kelly S. Chien
Publikováno v:
British Journal of Haematology. 195:378-387
Programmed cell death protein 1 (PD-1) and PD-ligand 1 (PD-L1) expression is upregulated in cluster of differentiation 34 (CD34)+ bone marrow cells from patients with myelodysplastic syndromes (MDS). Hypomethylating agent (HMA) treatment results in f
Autor:
Courtney D. DiNardo, Veronica A Guerra, Nicholas J. Short, Elias Jabbour, Zeev Estrov, Guillermo Montalban-Bravo, Danielle Hammond, Kiran Naqvi, Sherry Pierce, Naveen Pemmaraju, Hagop M. Kantarjian, Jorge Ramos-Perez, Gautam Borthakur, Rashmi Kanagal-Shamanna, Koji Sasaki, Marina Konopleva, Tapan M. Kadia, Naval Daver, Farhad Ravandi, Guillermo Garcia-Manero
Publikováno v:
Leukemia. 35:1494-1499
Publikováno v:
Cancer. 127:1186-1207
The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in rapid translation of the information into clinical practice. After more than 40 years of slow progress in AML research, the US Food and Drug Administration has appr
Autor:
Caitlin R. Rausch, Kiran Naqvi, Prithviraj Bose, Wei Qiao, Zeev Estrov, Musa Yilmaz, Kayleigh Marx, Xuelin Huang, Carol Bivins, David McCue, Tapan M. Kadia, Lucia Masarova, Naval Daver, Dimitrios P. Kontoyiannis, Naveen Pemmaraju, Hagop M. Kantarjian, Nathan P. Wiederhold, Koichi Takahashi, Farhad Ravandi, Sherry Pierce, Sebastian Wurster, Marina Konopleva, Gautam Borthakur
Publikováno v:
Clin Infect Dis
Background Mold-active primary antifungal prophylaxis (PAP) is routinely recommended in neutropenic patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) undergoing remission-induction chemotherapy (RI
Autor:
Joseph D. Khoury, Hagop M. Kantarjian, Naval Daver, Rashmi Kanagal-Shamanna, Kiran Naqvi, Mark J. Routbort, Gautam Borthakur, Jorge E. Cortes, Tapan M. Kadia, Nicholas J. Short, Koichi Takahashi, Farhad Ravandi, Keyur P. Patel, Elias Jabbour, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Koji Sasaki, Carlos E. Bueso-Ramos, Marina Konopleva, Ghayas C. Issa, Courtney D. DiNardo, Sherry Pierce, Caleb A. Class, Kim Anh Do
Publikováno v:
American Journal of Hematology. 95:612-622
Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is a heterogeneous disorder defined by multilineage dysplasia, myelodysplastic syndrome (MDS)-related karyotype, or history of prior MDS. We evaluated 415 patients with AML-MRC trea
Publikováno v:
Leukemia & Lymphoma. 61:288-297
For decades, the standard induction for patients with acute myeloid leukemia (AML) has been the combination of cytarabine with anthracycline (7 + 3 regimen). In August 2017 the US FDA approved CPX-351 (vyxeos), a liposomal formulation of cytarabine a
Autor:
Rebecca S. S. Tidwell, Sa A. Wang, Naval Daver, Musa Yilmaz, Yesid Alvarado, Farhad Ravandi, Tapan M. Kadia, Courtney D. DiNardo, Naveen Pemmaraju, Guillermo Garcia-Manero, Nitin Jain, Nicholas J. Short, Steven M. Kornblau, Gautam Borthakur, Rabiul Islam, Hagop M. Kantarjian, Patrick K. Reville, Marina Konopleva
Publikováno v:
Lancet Haematol
Summary Background Addition of the BCL2 inhibitor venetoclax to lower intensity therapy has been shown to improve overall survival in older (aged 75 years or older) and unfit patients with newly diagnosed acute myeloid leukaemia. The aim of this stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d51d3854846c1936e9e71a1b7fa758e
https://europepmc.org/articles/PMC8884174/
https://europepmc.org/articles/PMC8884174/
Autor:
Rashmi Kanagal-Shamanna, Mark J. Routbort, Yue Wei, Koji Sasaki, Carlos E. Bueso-Ramos, Faezeh Darbaniyan, Kelly A. Soltysiak, Tapan M. Kadia, Farhad Ravandi, Hagop M. Kantarjian, Sherry Pierce, Guillermo Garcia-Manero, Gautam Borthakur, Kelly S. Chien, L. Jeffrey Medeiros, Keyur P. Patel, Guillermo Montalban-Bravo, Elias Jabbour
Publikováno v:
Cancer
Background SF3B1 mutations (SF3B1mut ) in myelodysplastic syndromes (MDS) frequently involve codon K700E and have a favorable prognosis. The prognostic effect of non-K700E SF3B1mut is uncertain. Methods The authors analyzed the clinicopathological fe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69d1dc288395a350e33fc2b107e7e04d
https://europepmc.org/articles/PMC10015977/
https://europepmc.org/articles/PMC10015977/
Autor:
Elias Jabbour, Rosmy B. John, Graciela M. Nogueras González, Stefan Faderl, Kelly S. Chien, Zeev Estrov, Koji Sasaki, Farhad Ravandi, Guillermo Garcia-Manero, Xiao Qin Dong, Tapan M. Kadia, Kiran Naqvi, Heather Schneider, Guillermo Montalban Bravo, Hagop M. Kantarjian
Publikováno v:
Blood. 136:1-3
INTRODUCTION: Hypomethylating agents (HMAs) are the standard of care of patients (pts) with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). HMA failure is associated with poor outcomes, with a median survival o